Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Targeted delivery of microRNA-34a (miR-34a) for prostate cancer (PCa) therapy is challenging. Folate-conjugated miR-34a effectively targets other cancers but not PCa due to low receptor expression, hindering therapeutic development.
Area Of Science
- Oncology
- Molecular Biology
- Drug Delivery
Background
- Prostate cancer (PCa) is a leading cause of cancer mortality in men, often driven by heterogeneous cancer stem cells (PCSCs) that confer treatment resistance.
- MicroRNA-34a (miR-34a) shows therapeutic potential against PCSCs by targeting key survival pathways, but its clinical application is limited by delivery challenges and toxicity.
- Ligand-mediated delivery, such as folate conjugation, aims to improve miR-34a specificity and reduce side effects, showing success in other cancer types.
Purpose Of The Study
- To investigate the efficacy and targeted delivery of folate-conjugated miR-34a (folate-miR-34a) in prostate cancer.
- To evaluate the expression of folate receptor alpha (FOLR1) and prostate-specific membrane antigen (PSMA) in PCa cells as potential targets for folate-miR-34a delivery.
- To understand the challenges and opportunities for developing ligand-conjugated miR-34a therapeutics for PCa.
Main Methods
- Assessed miR-34a levels in PCa with TP53 alterations.
- Transfected PCa cells with miR-34a mimic to evaluate its effect on target gene expression and cell growth.
- Tested the anti-tumor efficacy and targeted delivery of folate-miR-34a in various cancer cell lines, including PCa, and analyzed FOLR1 and PSMA expression.
Main Results
- miR-34a levels were reduced in PCa with TP53 loss or mutations; miR-34a mimic transfection inhibited PCa cell growth.
- Folate-miR-34a demonstrated significant anti-tumor effects in breast, ovarian, and cervical cancer cells.
- Folate-miR-34a showed minimal efficacy and targeted delivery in PCa cells, correlating with low FOLR1 expression and lack of folate binding to PSMA.
Conclusions
- The therapeutic potential of folate-miR-34a for PCa is limited by the insufficient expression of target receptors like FOLR1 and PSMA on PCa cells.
- Targeted delivery strategies for miR-34a in PCa require alternative ligands or approaches that address the specific receptor landscape of prostate cancer.
- This study highlights critical challenges in developing ligand-conjugated miR-34a therapeutics for PCa, necessitating further research into novel delivery mechanisms.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...